EVOLITO-LIMITED
Evolito Limited, the pioneer of world-leading axial-flux electric motors, power electronics, and battery solutions for aerospace applications, announces the appointment of Marc Holme as CTO, as it prepares for future growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416821458/en/
Marc Holme, CTO, Evolito (Photo: Business Wire)
Marc Holme joins as CTO to lead the technology development and the future roadmap of the axial-flux e-motor and propulsion product family. He has a 24-year tenure in aviation, most recently at Collins Aerospace where he was Senior Director of Engineering. Holme’s deep technical background has seen him lead multiple aircraft system electrification programs from Airbus A380 to Boeing 787, and many technology acquisition programs.
Commenting on his appointment, Marc Holme, CTO, Evolito said:
“I’m excited to join Evolito to continue the progression towards more sustainable aviation through electrification. The advanced electric motor technology that originated for the automotive market is being adapted and improved by Evolito to enable aerospace applications where weight, efficiency and safety are critical. Combined with its leading motor control electronics and battery technologies, Evolito is well positioned to reach scalable and sustainable electric aviation.”
The new C-suite hire follows a phenomenal year for the company, having received Design Organisation Approval (DOA) from the UK Civil Aviation Authority for electric propulsion system products in December 2023. Evolito is already working with a number of OEM partners, developing motors and propulsion systems for a variety of eVTOL, Urban Air Mobility and fixed-wing applications, and expects a series of customer test flights later this year.
Dr. Chris Harris, Evolito CEO and co-founder said:
“The whole company is delighted to welcome Marc to the growing Evolito family. I’m extremely proud of what we have created here at Evolito, and our success is a reflection of our hugely talented and dedicated team, driven by a common passion for sustainable mobility. The electrification of flight is one of the most exciting market opportunities of our time, and Evolito’s innovative new technology and ability to scale means we are well positioned to meet this fast-emerging demand.”
Founded in July 2021, Evolito has grown its experienced team from 15 to over 200. It was recently awarded 2nd place in four award categories in the 2023 Best Companies100 Best Place To Work. In July 2022, Evolito acquired and later integrated Electroflight batteries into the business to offer complete propulsion solutions that are fully optimised for future aircraft applications. Amongst other partners, it works with Cranfield Aerospace Solutions who provide motor and inverters for its hydrogen aircraft demonstrator - the Fresson project.
EDITOR’S NOTES
Evolito
Evolito is making all-electric flight a reality by offering world-leading electric axial flux motors, motor control units and battery systems for the aerospace market. Evolito’s electric propulsion systems offer the highest power, torque, and energy densities in class and are inherently more robust than alternative technologies – mission critical in eVTOL, Urban Air Mobility and fixed-wing applications. The privately-held company is based in Oxford. Evolito’s investors include B-Flexion and Oxford Science Enterprises (OSE).
Marc Holme, CTO, Evolito boasts 24 years of experience in aviation and a further 5 in automotive. Prior to joining Evolito, Holme was Senior Director Engineering at Collins Aerospace. He has also worked for UTC Aerospace Systems and Goodrich. Holme has a masters in power electronics and drives from The University of Birmingham.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416821458/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 08:00:00 CEST | Press release
Collaboration brings together Shield's AI-first platform with PwC's surveillance expertise to deliver measurable compliance outcomes Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with co
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 08:00:00 CEST | Press release
Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with moderate-to-severe psoriasis over two years.POSITIVE is the first real-world evidence (RWE) study in dermatology to use the WHO-5 Well-Being Index as a primary endpoint, complementing traditional measures of skin disease (PASI, PGA), quality of life (DLQI), with the assessment of psychological well-being, marking a paradigm shift towards holistic management of psoriasis.The POSITIVE study highlights Almirall’s leadership in advancing patient-centred dermatology aligned with the WHO’s health definition and recent resolution on skin diseases.Almirall’s extensive scientific contributions to EADV 2025 include 44 abstracts across key dermatological conditions including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa, and two expert-led symposia. Almirall, S.A. (ALM
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 07:00:00 CEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay18.9.2025 07:00:00 CEST | Press release
Cetaphil's new Skin Activator Hydrating & Firming Line harnesses a proprietary formula, co-created with dermatologists and offering targeted, high-performance skincare designed to improve the appearance of skin affected by dermatoporosis The line’s new Skin Activator technology uses microdosed alpha hydroxy acid (AHA) and encapsulated centella asiatica (CICA) to wake up sleeping surface skin cells To help bring this segment-defining product line to life, Cetaphil is partnering with acclaimed actress, director, and advocate, Mariska Hargitay, a powerful voice in embracing beauty at every stage Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface
Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland18.9.2025 07:00:00 CEST | Press release
Part of company’s €440 million investment in Ireland, strengthens Merck’s in-region-for-region supply resilienceMerck’s first climate-neutral manufacturing facility, powered by 100 percent renewable electricityNew Blarney site in Cork, Ireland expands filter manufacturing capacity, creating more than 200 jobs by 2028 Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917767425/en/ Merck's new Blarney site in Cork expands company's filter capacity, creating 200+ jobs by 2028 The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom